QLT, Sanofi Settle Patent Dispute With TAP Over Prostate Cancer Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
TAP receives combined $157.5 million to end patent conflict between TAP’s Lupron Depot and QLT/Sanofi-Aventis’ Eligard.